Why is Moderna important to traders?
Moderna is an American biotechnology company, pioneering in the development of a new class of medicines made of messenger RNA (mRNA). The company believes that using mRNA as a drug could significantly improve the process of medicines discovery, development and production.
Founded in 2010, Moderna has built the industry’s leading mRNA technology platform, capable of accelerating early development of vaccines and discovering drugs.
In early November 2020, Moderna announced its vaccine against Covid-19 showed more than 94 per cent effectiveness. The company’s vaccine has a major advantage over the rival vaccine from Pfizer, as it can be stored at just 2 to 80 C, while Pfizer’s vaccine requires -700 C.
Moderna went public in December 2018 during the largest biotech IPO in history. The company raised $600m for 8 per cent of its shares with a valuation of $7.5bn. The company’s stock is listed and traded on the NASDAQ stock exchange under the ticker symbol MRNA. It is also a constituent of the NASDAQ 100 stock market index.
Moderna stock trading hours
If you choose to trade CFDs, you can follow the Moderna stock performance live in US dollars with the comprehensive Moderna stock price chart at Capital.com:
Monday to Friday from 14:30 to 21:00.
This gives you plenty of time to monitor the company’s activity and keep an eye out for any events that may affect short-term movements in the Moderna stock value.
How to trade Moderna shares with CFDs
An individual has two options when trading in the stock market. Firstly, they can buy shares in companies on the exchanges where they are listed. For instance, investing in Moderna stocks on the NASDAQ you actually acquire a share in the company. This can be considered a long-term investment, as the individual is usually waiting for the price to rise over time.
Alternatively, they can trade a contract for difference (CFD) for the Moderna stock market price, and speculate on its difference without actually owning the asset. A CFD is a financial contract, typically between a broker and an investor, where one party agrees to pay the other the difference in the value of a security, between the opening and closing of the trade.
You can either hold a long position (speculating that the price will rise) or a short position (speculating that the price will fall). This is considered a short-term investment or trade, as CFDs tend to be used within shorter timeframes.
The key difference between Moderna share trading through a long position with a CFD and buying a security is the leverage that is employed. CFDs are traded on margin, which means that a trader can open larger positions with their capital.
You can trade Moderna stock with CFDs right now. Just sign up at Capital.com and use our advanced web platform or download the best-in-class investment app to trade on the go. It will take you just three minutes to get started and access the world’s most traded markets.
Trade Moderna, Inc. - MRNA CFD
Why trade Moderna CFDs with Capital.com
Advanced AI technology at its core: A Facebook-like News Feed provides users with personalised and unique content depending on their preferences. If a trader makes decisions based on biases, the innovative News Feed offers a range of materials to put you back on the right track. The neural network analyses in-app behaviour and recommends videos, articles, news to polish your investment strategy.
Trading on margin: Providing trading on margin (up to 5:1 for individual equities), Capital.com gives you access to the Moderna shares trading with the help of CFDs.
Trading the difference: When you invest in Moderna shares with CFDs, you don’t buy the underlying asset itself, meaning you are not tied to it. You only speculate on the rise or fall of the Moderna stock performance. CFD trading is nothing different from traditional trading in terms of strategies. A CFD investor can go short or long, set stop and limit losses and apply trading scenarios that align with their objectives.
All-round trading analysis: The browser-based platform allows traders to shape their own market analysis and forecasts with sleek technical indicators. Capital.com provides live market updates and various chart formats, available on desktop, iOS, and Android.
Focus on safety: Captal.com puts a special emphasis on safety. Licensed by the FCA and CySEC, it complies with all regulations and ensures that its clients’ data security comes first. The company allows you to withdraw money 24/7 and keeps traders’ funds across segregated bank accounts.
Moderna share price history
Moderna was incorporated in 2010 as ModeRNA Therapeutics with the aim to commercialise the research of stem cell biologist Derrick Rossi. The scientist introduced the way to modify mRNA by transferring it into human cells.
In March 2013, Moderna signed a five-year agreement with AstraZeneca to discover, develop and commercialise messenger RNA for treatments in various therapeutic areas, including metabolic and cardiovascular diseases and different cancer types.
In 2018 the company rebranded as Moderna Inc and went public on the NASDAQ with the ticker symbol MRNA. This happened to be the major biotech IPO in history. The company got $621m offering 27 million shares at $23 each, which resulted in a company’s valuation of $7.5bn.
Until 2020, the Moderna shares had been trading rather flatly within a range of $18 – $28. This year the situation has drastically changed, mainly due to the company’s involvement in coronavirus vaccine development and its successful trials.
Moderna share price history chart
Is Modern stock a good investment?
The MRNA stock climbed from $17.68 on January 7, 2020 to $109.29 on November 25, 2020, following a long-term price rally. The successful performance during the year and prospects to save the world from the coronavirus pandemic contributes to a positive Moderna stock forecast next year and beyond.
With Capital.com’s streaming Moderna stock chart, you can quickly view the price of MRNA stock in real time and trace the best levels to open a profitable CFD trade.
Among Moderna’s major competitors we can define the following brands:
AstraZeneca is a British-Swedish international biopharmaceutical company, headquartered in Cambridge, UK. The company has a portfolio of treatments of major diseases, including cancer, gastrointestinal, cardio, infection, respiratory and other areas. The company has developed its own vaccine against Covid-19, which is now being tested and widely discussed in the media.
BioNTech is a German biotechnology company, focused on the research and development of active individualised immunotherapies. In partnership with the US-based Pfizer, it developed the mRNA-vaccine from Covid-19, which showed over 90 per cent effectiveness during the phase-three clinical trials.
Gilead Sciences is an American biopharmaceutical company. Its portfolio includes medicals for HIV prevention and treatment. They also produce medical products serving to cure cardiovascular, oncological and other severe diseases. Today, the company is well-known as the producer of antiviral drug Remdesivir, used as a treatment for Covid-19, although its efficiency was found doubtful according to the recent study by the WHO.
As with any equity, quarterly earnings announcements and the financial performance of the wider stock market are two crucial factors to watch when deciding how Moderna stock will perform.
Commenting on the company’s performance and financial results for the third quarter of 2020, Stéphane Bancel, Chief Executive Officer of Moderna, said: “The Moderna team continued to execute on our plan in the third quarter. We now have four programs in Phase 2 studies, in addition to the Phase 3 study of our COVID-19 vaccine, mRNA-1273, which is fully enrolled. Our CMV vaccine showed positive interim Phase 2 data and we are now preparing for the Phase 3 start in 2021. We are actively preparing for the launch of mRNA-1273 and we have signed a number of supply agreements with governments around the world. Moderna is committed to the highest data quality standards and rigorous scientific research as we continue to work with regulators to advance mRNA-1273.
I believe that if we launch our COVID-19 vaccine, 2021 could be the most important inflection year in Moderna’s history. We will have the resources to scale Moderna to maximize the impact we can have on patients in the next 10 years through numerous new medicines.”
Revenue: total revenue was $157.9m for the three months ended September 30, 2020 compared to $17.0m for the same period in 2019. The jump in revenue was triggered by the received grants. The biggest one – $472m – was provided in July 2020 to support studies of mRNA-1273 vaccine.
Loss per share: Moderna announced a Q3 loss of $233.6 m, or $0.59 per share, compared to a loss of $123.2m, or $0.37 per share for the same period in 2019.